(S)-8-(4-(bis(4-fluorophenyl)methyl)-3-methylpiperazin-1-yl)-7-chloro-5-methyl-6-oxo-5,6-dihydro-1,5-naphthyridine-2-carbonitrile

ID: ALA4637336

Chembl Id: CHEMBL4637336

PubChem CID: 146466515

Max Phase: Preclinical

Molecular Formula: C28H24ClF2N5O

Molecular Weight: 519.98

Molecule Type: Unknown

Associated Items:

Names and Identifiers

Canonical SMILES:  C[C@H]1CN(c2c(Cl)c(=O)n(C)c3ccc(C#N)nc23)CCN1C(c1ccc(F)cc1)c1ccc(F)cc1

Standard InChI:  InChI=1S/C28H24ClF2N5O/c1-17-16-35(27-24(29)28(37)34(2)23-12-11-22(15-32)33-25(23)27)13-14-36(17)26(18-3-7-20(30)8-4-18)19-5-9-21(31)10-6-19/h3-12,17,26H,13-14,16H2,1-2H3/t17-/m0/s1

Standard InChI Key:  UFIZEEXQYAMFJQ-KRWDZBQOSA-N

Alternative Forms

  1. Parent:

    ALA4637336

    ---

Associated Targets(Human)

DGKA Tbio Diacylglycerol kinase alpha (73 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
DGKZ Tchem Diacylglycerol kinase zeta (13 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
DGKA Tbio Diacylglycerol kinase alpha/zeta (14 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 519.98Molecular Weight (Monoisotopic): 519.1637AlogP: 5.04#Rotatable Bonds: 4
Polar Surface Area: 65.16Molecular Species: NEUTRALHBA: 6HBD:
#RO5 Violations: 2HBA (Lipinski): 6HBD (Lipinski): #RO5 Violations (Lipinski): 2
CX Acidic pKa: CX Basic pKa: 6.00CX LogP: 5.01CX LogD: 5.00
Aromatic Rings: 4Heavy Atoms: 37QED Weighted: 0.38Np Likeness Score: -0.97

References

1. Abdel-Magid AF..  (2020)  Cancer Immunotherapy through the Inhibition of Diacylglycerol Kinases Alpha and Zeta.,  11  (6): [PMID:32550982] [10.1021/acsmedchemlett.0c00118]

Source